Organizations will use mesenchymal stem cells to pursue new therapies for a variety of degenerative disorders.
Pluristem Life Systems inked a research agreement with the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) at Charité-University Medicine Berlin. Pluristem and BCRT will explore a variety of indications utilizing mesenchymal stem cells (MSCs) derived from the placenta that have been expanded in the company’s PluriX™ 3-D bioreactor.
The initial focus of the alliance will be on neurological indications such as multiple sclerosis and Parkinson’s disease. The agreement also covers organ transplantation and cardiovascular indications like inflammatory cardiomyopathy. Pluristem will be the exclusive owner of the technology and any products stemming from the collaboration.